8.66

7.71% 0.62

After Hours: 8.60 -0.06 -0.69%

Aligos Therapeutics Inc (ALGS)

Overview News Price History Option Chain Financials Why ALGS Down? Discussions Forecast

Aligos Therapeutics Inc stock is traded at $8.66, with a volume of 77,726. It is up +7.71% in the last 24 hours and down -31.70% over the past month. Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Previous Close:

$8.04

Open:

$7.96

24h Volume:

77,726

Relative Volume:

1.33

Market Cap:

$29.02M

Revenue:

$15.53M

Net Income/Loss:

$-87.68M

P/E Ratio:

-4.534

EPS:

-1.91

Net Cash Flow:

$-79.02M

1W Performance:

+6.91%

1M Performance:

-31.70%

6M Performance:

-64.65%

1Y Performance:

-53.63%

1-Day Range:

$7.96

$9.77

1-Week Range:

$7.35

$9.77

52-Week Range:

$7.35

$30.00

Aligos Therapeutics Inc Stock (ALGS) Company Profile

Name

Aligos Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(800) 466-6059

Address

ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

ALGS's Discussions on Twitter

Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-23	Upgrade	Jefferies	Hold → Buy
Jan-06-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-23-22	Downgrade	Piper Sandler	Overweight → Neutral
Jan-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-22	Downgrade	Jefferies	Buy → Hold
Sep-09-21	Initiated	SVB Leerink	Outperform
May-17-21	Resumed	Piper Sandler	Overweight
Nov-10-20	Initiated	Cantor Fitzgerald	Overweight
Nov-10-20	Initiated	JP Morgan	Overweight
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Aligos Therapeutics Inc Stock (ALGS) Latest News

01:00 AM

Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume - MarketBeat

01:00 AM

08:09 AM

Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times

08:09 AM

08:00 AM

Aligos Therapeutics to Present at Investor Conferences in October - StockTitan

08:00 AM

Sep 26, 2024

(ALGS) Investment Analysis and Advice - Stock Traders Daily

Sep 26, 2024

Sep 24, 2024

Aligos Therapeutics keeps stock target, overweight rating on promising data - Investing.com

Sep 24, 2024

Aligos Therapeutics keeps stock target, overweight rating on promising data By Investing.com - Investing.com Canada

Sep 24, 2024

ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Sep 24, 2024

Aligos Therapeutics names new chief medical officer - Investing.com

Sep 24, 2024

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - StockTitan

Sep 24, 2024

Sep 23, 2024

Aligos Therapeutics stock hits 52-week low at $8.5 - Investing.com

Sep 23, 2024

Aligos Therapeutics stock hits 52-week low at $8.5 By Investing.com - Investing.com Canada

Sep 23, 2024

Aligos Therapeutics (NASDAQ:ALGS) Sets New 52-Week Low at $8.28 - MarketBeat

Sep 23, 2024

Aligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28 - Defense World

Sep 23, 2024

Sep 21, 2024

Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - Defense World

Sep 21, 2024

Sep 20, 2024

Aligos Therapeutics' (ALGS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Sep 20, 2024

Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $10.18 - MarketBeat

Sep 20, 2024

Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright - Defense World

Sep 20, 2024

Market Recap Check: Aligos Therapeutics Inc (ALGS)’s Negative Finish at 10.18, Up/Down -28.11 - The Dwinnex

Sep 20, 2024

Aligos Phase II results for ALG-055009 in MASH fail to impress - The Pharma Letter

Sep 20, 2024

Aligos shares maintain Buy rating with price target after study - Investing.com

Sep 20, 2024

Aligos reports positive data from Phase IIa MASH treatment trial - Clinical Trials Arena

Sep 20, 2024

Aligos reports progress in MASH treatment study - Investing.com

Sep 20, 2024

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - Markets Insider

Sep 20, 2024

Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - MarketBeat

Sep 20, 2024

Sep 19, 2024

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - ForexTV.com

Sep 19, 2024

Aligos’s MASH Data Look Competitive, But Path Forward Is Unclear - Scrip

Sep 19, 2024

How will Aligos Therapeutics Inc’s (ALGS) earnings compare to estimates this quarter? - US Post News

Sep 19, 2024

Hark, Herald MASH phase II positive but Aligos THRown for a loop - BioWorld Online

Sep 19, 2024

Aligos reports progress in MASH treatment study - Investing.com India

Sep 19, 2024

Aligos stock falls on data for MASH candidate (NASDAQ:ALGS) - Seeking Alpha

Sep 19, 2024

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - 新浪香港

Sep 19, 2024

Aligos' fatty liver disease treatment meets main goal in mid-stage study - Reuters

Sep 19, 2024

Aligos Therapeutics Announces Positive Topline Results from - GlobeNewswire

Sep 19, 2024